1. Home
  2. BTDR vs VIR Comparison

BTDR vs VIR Comparison

Compare BTDR & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bitdeer Technologies Group

BTDR

Bitdeer Technologies Group

N/A

Current Price

$5.58

Market Cap

1.6B

Sector

Technology

ML Signal

N/A

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

N/A

Current Price

$9.76

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTDR
VIR
Founded
2021
2016
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
BTDR
VIR
Price
$5.58
$9.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
8
Target Price
$20.92
★ $23.38
AVG Volume (30 Days)
★ 10.1M
1.8M
Earning Date
11-10-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 17.49
EPS
★ N/A
N/A
Revenue
N/A
★ $68,556,000.00
Revenue This Year
$54.56
$305.75
Revenue Next Year
$70.16
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$5.03
$5.32
52 Week High
$20.72
$14.38

Technical Indicators

Market Signals
Indicator
BTDR
VIR
Relative Strength Index (RSI) 36.09 39.70
Support Level $5.03 $8.23
Resistance Level $13.15 $10.32
Average True Range (ATR) 0.73 0.80
MACD 0.05 -0.06
Stochastic Oscillator 19.28 1.39

Price Performance

Historical Comparison
BTDR
VIR

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in the provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: